PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-35.03%
Both companies show negative EBIT growth. Martin Whitman would consider macro or sector-specific headwinds.
-35.03%
Both companies face negative operating income growth. Martin Whitman would suspect broader market or cost hurdles.
-37.55%
Both companies face declining net income. Martin Whitman would suspect external pressures or flawed business models in the space.
-34.88%
Negative EPS growth while AGEN is at 95.07%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-34.88%
Negative diluted EPS growth while AGEN is at 95.15%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
2.03%
Share reduction more than 1.5x AGEN's 2078.15%. David Dodd would see if the company is taking advantage of undervaluation to retire shares.
2.03%
Diluted share reduction more than 1.5x AGEN's 2116.20%. David Dodd would validate if the company is aggressively retiring shares or limiting option exercises.
No Data
No Data available this quarter, please select a different quarter.
9.51%
OCF growth under 50% of AGEN's 23.99%. Michael Burry might suspect questionable revenue recognition or rising costs.
9.65%
FCF growth 50-75% of AGEN's 18.96%. Martin Whitman would see if structural disadvantages exist in generating free cash.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
63.42%
10Y OCF/share CAGR above 1.5x AGEN's 36.66%. David Dodd would check if a superior product mix or cost edge drives this outperformance.
54.54%
5Y OCF/share CAGR is similar to AGEN's 55.65%. Walter Schloss might see parallel cost profiles or expansions producing comparable cash flow.
-31.27%
Negative 3Y OCF/share CAGR while AGEN stands at 41.71%. Joel Greenblatt would demand an urgent turnaround in the firm’s cost or revenue drivers.
85.15%
Net income/share CAGR above 1.5x AGEN's 46.86% over 10 years. David Dodd would confirm if brand, IP, or scale secure this persistent advantage.
56.20%
5Y net income/share CAGR above 1.5x AGEN's 9.41%. David Dodd would confirm if the firm’s strategy is more effective in generating mid-term profits.
-42.46%
Negative 3Y CAGR while AGEN is 24.26%. Joel Greenblatt might call for a short-term turnaround strategy or cost realignment.
-24.53%
Negative equity/share CAGR over 10 years while AGEN stands at 56.47%. Joel Greenblatt sees a fundamental red flag unless the competitor also struggles.
-57.00%
Negative 5Y equity/share growth while AGEN is at 74.83%. Joel Greenblatt sees the competitor building net worth while this firm loses ground.
-54.63%
Negative 3Y equity/share growth while AGEN is at 79.12%. Joel Greenblatt demands an urgent fix in capital structure or profitability vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-2.92%
Both reduce assets yoy. Martin Whitman suspects a broader sector retraction or post-boom asset trimming cycle.
-9.07%
We have a declining book value while AGEN shows 93.36%. Joel Greenblatt sees a fundamental disadvantage in net worth creation vs. the competitor.
-5.00%
Both reduce debt yoy. Martin Whitman sees a broader sector shift to safer balance sheets or less growth impetus.
41.18%
R&D growth of 41.18% while AGEN is zero. Bruce Berkowitz checks if the moderate investment leads to meaningful product differentiation.
22.12%
SG&A growth well above AGEN's 11.94%. Michael Burry sees potential margin erosion unless it translates into higher sales or brand equity.